Revvity (NYSE:RVTY) Given New $106.00 Price Target at Evercore ISI

Revvity (NYSE:RVTY) had its price objective trimmed by Evercore ISI from $108.00 to $106.00 in a research report report published on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 3rd. Stifel Nicolaus lowered their price objective on shares of Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a research note on Tuesday, July 29th. Raymond James Financial reissued an “outperform” rating and issued a $115.00 price objective (down from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Weiss Ratings reissued a “hold (c-)” rating on shares of Revvity in a research note on Saturday, September 27th. Finally, Bank of America lowered their price objective on shares of Revvity from $110.00 to $99.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Ten analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Revvity has an average rating of “Moderate Buy” and a consensus target price of $117.93.

Revvity Trading Down 2.3%

Shares of Revvity stock opened at $91.20 on Tuesday. The company has a fifty day simple moving average of $87.98 and a 200-day simple moving average of $93.19. Revvity has a 12-month low of $81.36 and a 12-month high of $129.50. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $10.59 billion, a price-to-earnings ratio of 38.65, a PEG ratio of 3.12 and a beta of 0.98.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm had revenue of $720.28 million during the quarter, compared to the consensus estimate of $711.26 million. During the same quarter in the prior year, the firm earned $1.22 EPS. Revvity’s revenue for the quarter was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, equities analysts forecast that Revvity will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Friday, October 17th. Revvity’s dividend payout ratio (DPR) is currently 11.86%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RVTY. Price T Rowe Associates Inc. MD raised its holdings in Revvity by 25.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company’s stock valued at $1,011,863,000 after buying an additional 1,932,314 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in Revvity by 8.5% in the first quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company’s stock valued at $2,382,163,000 after buying an additional 1,754,403 shares during the period. EdgePoint Investment Group Inc. raised its holdings in Revvity by 26.7% in the second quarter. EdgePoint Investment Group Inc. now owns 6,789,660 shares of the company’s stock valued at $656,696,000 after buying an additional 1,428,813 shares during the period. Norges Bank purchased a new position in Revvity in the second quarter valued at approximately $124,574,000. Finally, Invesco Ltd. raised its holdings in Revvity by 25.8% in the second quarter. Invesco Ltd. now owns 2,207,202 shares of the company’s stock valued at $213,481,000 after buying an additional 452,343 shares during the period. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.